Genoscience Pharma History

Genoscience Pharma was founded by Philippe Halfon, a renowned expert in the field of infectious diseases. Genoscience Pharma was initially dedicated to the development of antiviral compounds against Hepatitis C virus. Several protease inhibitors were developed, leading to the discovery of a new chemical entity family inhibiting autophagy, and efficient against Hepatitis C virus. Because of encouraging results of its autophagy inhibitors drug candidates in cancer stem cell lines, Genoscience Pharma has reoriented its focus on oncology, where  medical needs are still unmet.

Start of Operations in 20022001
Several HCV inhibitors identified : Licensing out of GNS227 in 20122007-2012
New Therapeutic Area
New focus in oncology after the discovery of a new chemical entity family, with a new mechanism of action, targeting the lysosomal compartment and zinc transporters2012-2016
Clinical Trial
GNS561 in Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: First-in-Human in April 2018

GNS396 compound in Acute Myeloid Leukemia and Colorectal Cancer : Preclinical development2018